ArticleNature2022
Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 219 papers.
0numbers the graph read from it
0cells of the map it votes in
219citing papers in PubMed
42.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
219 citing papers in PubMed, 317 citations in OpenAlex.
- Article
- ITGBL1-MYH9 interaction in hepatic stellate cells acts as a mechanoregulator controlling liver fibrosis in mice.The Journal of clinical investigation · 2026Article
- Hepatic stellate cells promote structural and functional remodeling of three-dimensional hepatocellular carcinoma coculture spheroids.Molecular biology reports · 2026Article
- Dysregulated mScience advances · 2026Article
- Matrix stiffness shapes early transcriptional trajectories during hepatic stellate cell activation.Hepatology international · 2026Article
- Piezo ion channels in the digestive system: Mechanotransduction pathways and therapeutic targeting strategies.Genes & diseases · 2026Review
- Hepatic stellate cell subpopulations in human MASLD-related hepatocellular carcinoma upregulate YAP via geranylgeranyl pyrophosphate.Hepatology communications · 2026Article
- Molecular mechanisms and pathogenesis of MASH.Nature · 2026Review
- Context-dependent duality of senescent cells in liver fibrosis.Liver research (Beijing, China) · 2026Review
- UBE2N deficiency contributes to MASH development via p62-regulated mitophagy and PANoptosis.Nature metabolism · 2026Article
- Exploring the role of inflammatory cytokines in obesity-mediated MASLD development and drug target identification.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- TGFβ activity stabilizes ACC1 to increase de novo lipogenesis in metabolic liver disease.Molecular metabolism · 2026Article
- Article
- Metabolically and epigenetically reprogrammed splenic TRNP1Nature genetics · 2026Article
- Integrative multi-omics analysis identifies stellate cell-derived complement component 7 as a predictor of fibrosis and liver-related events in MASLD.JHEP reports : innovation in hepatology · 2026Article
- Molecular phenotypes and spatial archetypes: A new framework for cancer-associated fibroblasts.Cancer cell · 2026Review
- Shared mechanisms of organ fibrosis.JCI insight · 2026Review
- Fibroblasts: a diverse population of cells balancing homeostasis, wound healing, regeneration, inflammation, fibrosis, and cancer across organs.JCI insight · 2026Review
- Transcriptional co-activators YAP/TAZ in cancer-associated fibroblasts are dispensable for Notch-driven intrahepatic cholangiocarcinoma.Journal of molecular cell biology · 2026Article
- From steatosis to metastasis: microenvironmental reprogramming of the liver in metabolic dysfunction-associated steatotic liver disease.Clinical and molecular hepatology · 2026Review
159 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 12 institutions in 6 countries.
Aveline FilliolDepartment of Medicine, Columbia University, New York, NY, USA.
Yoshinobu Saito *Department of Medicine, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0002-0624-0449
Ajay Nair *Department of Medicine, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0003-4521-5614
Dianne H Dapito *Department of Medicine, Columbia University, New York, NY, USA.
Le-Xing Yu *Department of Medicine, Columbia University, New York, NY, USA.
Aashreya RavichandraDepartment of Medicine, Columbia University, New York, NY, USA.
Sonakshi BhattacharjeeDepartment of Medicine, Columbia University, New York, NY, USA.
Silvia AffoDepartment of Medicine, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0002-9731-3913
Naoto FujiwaraLiver Tumor Translational Research Program, Harold C. Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0002-4109-3421
Hua SuDepartment of Pharmacology, School of Medicine, University of California, San Diego, San Diego, CA, USA.
Qiuyan SunDepartment of Medicine, Columbia University, New York, NY, USA.
Thomas M SavageDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-6618-2973
John R Wilson-KanamoriCentre for Inflammation Research, The Queen's Medical Research Institute, Edinburgh BioQuarter, University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0002-1372-9912
Jorge M CavigliaDepartment of Medicine, Columbia University, New York, NY, USA.
LiKang ChinPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Dongning ChenPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Xiaobo WangDepartment of Medicine, Columbia University, New York, NY, USA.
Stefano CarusoFunctional Genomics of Solid Tumors Laboratory, Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Jin Ku KangDepartment of Medicine, Columbia University, New York, NY, USA.
Amit Dipak AminDepartment of Medicine, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0002-2613-2082
Sebastian WallaceCentre for Inflammation Research, The Queen's Medical Research Institute, Edinburgh BioQuarter, University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0002-1826-0551
Ross DobieCentre for Inflammation Research, The Queen's Medical Research Institute, Edinburgh BioQuarter, University of Edinburgh, Edinburgh, UK.
Deqi YinDepartment of Medicine, Columbia University, New York, NY, USA.
Oscar M Rodriguez-FiallosDepartment of Medicine, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0002-5087-3710
Chuan YinDepartment of Medicine, Columbia University, New York, NY, USA.
Adam MehalDepartment of Medicine, Columbia University, New York, NY, USA.
Benjamin IzarDepartment of Medicine, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0003-2379-6702
Richard A FriedmanBiomedical Informatics Shared Resource, Herbert Irving Comprehensive Cancer Center, and Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-5136-2998
Rebecca G WellsPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-6988-4102
Utpal B PajvaniDepartment of Medicine, Columbia University, New York, NY, USA.
Yujin HoshidaLiver Tumor Translational Research Program, Harold C. Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0001-9430-1426
Helen E RemottiDepartment of Pathology, Columbia University Irving Medical Center, New York, NY, USA.
Nicholas ArpaiaDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.
Jessica Zucman-RossiFunctional Genomics of Solid Tumors Laboratory, Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.ORCID http://orcid.org/0000-0002-5687-0334
Michael KarinDepartment of Pharmacology, School of Medicine, University of California, San Diego, San Diego, CA, USA.
Neil C HendersonCentre for Inflammation Research, The Queen's Medical Research Institute, Edinburgh BioQuarter, University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0002-2273-4094
Ira TabasDepartment of Medicine, Columbia University, New York, NY, USA.
Robert F SchwabeDepartment of Medicine, Columbia University, New York, NY, USA. rfs2102@cumc.columbia.edu.ORCID http://orcid.org/0000-0003-4571-2098
Columbia University · USColumbia University Irving Medical Center · USCentre for Inflammation Research · GBInserm · FRThe University of Texas Southwestern Medical Center · USUniversity of California San Diego · USUniversity of Pennsylvania · USCity University of New York · USConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESShanghai Changzheng Hospital · CNTUM Klinikum · DEWidener University · US
Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3MThe Organoid and Cell Culture CoreP30DK132710 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Robert F. Schwabe · 2022 to 2026
$7.2MThe effect of cancer cell produced collagen 1 homotrimers on DDR1 signaling activation by microenvironmental collagen 1 fragments.U01CA274295 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Karin, ANDREW M LOWY · 2022 to 2026
$5.2MRole of p62/SQSTM1 in obesity-induced liver cancerR01CA211794 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KARIN, MICHAEL, MOSCAT, JORGE · 2017 to 2021
$3.6MReverse-engineering precision liver cancer chemopreventionR01CA233794 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HOSHIDA, YUJIN · 2019 to 2023
$3.5MRole of Cancer-Associated Fibroblasts in CholangiocarcinomaR01CA228483 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CHEN, XIN, SCHWABE, ROBERT F. · 2018 to 2022
$3.1MHighly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitorsR01CA234128 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KARIN, MICHAEL · 2019 to 2023
$2.7MTAZ and YAP in Non-Alcoholic Steatohepatitis and its ComplicationsR01DK116620 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SCHWABE, ROBERT F., TABAS, IRA A · 2018 to 2021
$2.7MMechanisms of liver metastasis and associated resistance to immunotherapyR37CA258829 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Benjamin Izar · 2021 to 2026
$2.6MTumor-promoting and tumor-suppressive roles of Hepatic Stellate Cell Subpopulations in NASH-HCCR01CA262424 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SCHWABE, ROBERT F. · 2021 to 2025
$2.5MProtective and fibrosis-independent functions of hepatic stellate cellsR01DK128955 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SCHWABE, ROBERT F. · 2021 to 2024
$2.1MHepatic Stellate Cells and Liver CancerR01CA190844 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SCHWABE, ROBERT F. · 2015 to 2019
$1.8MMedical Research CouncilNCI NIH HHS P30 CA013696NCI NIH HHS R01 CA190844NCI NIH HHS R01 CA211794NCI NIH HHS R01 CA228483NCI NIH HHS R01 CA233794NCI NIH HHS R01 CA234128NCI NIH HHS R01 CA262424NCI NIH HHS R21 CA263381NCI NIH HHS R37 CA258829NCI NIH HHS U01 CA274295NIDDK NIH HHS F31 DK091980NIDDK NIH HHS P30 DK132710NIDDK NIH HHS R01 DK116620NIDDK NIH HHS R01 DK128955NIH HHS S10 OD020056Wellcome TrustWellcome Trust 219542/Z/19/Z
Abstract
Hepatocellular carcinoma (HCC), the fourth leading cause of cancer mortality worldwide, develops almost exclusively in patients with chronic liver disease and advanced fibrosis
Indexed as
CarcinogenesisCarcinoma, HepatocellularHepatic Stellate CellsLiver NeoplasmsAnimalsCell ProliferationCollagen Type IDiscoidin Domain Receptor 1Disease ProgressionHepatocyte Growth FactorHepatocytesHumansLiver CirrhosisMiceMyofibroblastsCollagen Type IDiscoidin Domain Receptor 1Hepatocyte Growth Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.